As physicians have increased opioid prescribing, overdose deaths from pharmaceutical opioids have substantially increased in the United States. Naloxone hydrochloride (naloxone), an opioid antagonist, is the standard of care for treatment of opioid induced respiratory depression. Since 1996, community-based programs have offered overdose prevention education and distributed naloxone for bystander administration to people who use opioids, particularly heroin. There is growing interest in translating overdose education and naloxone distribution (OEND) into conventional medical settings for patients who are prescribed pharmaceutical opioids. For this review, we summarized and classified existing publications on overdose education and naloxone distribution to identify evidence of effectiveness and opportunities for translation into conventional medical settings.
Methods
For this review, we searched English language PubMed for articles on naloxone based on primary data collection from humans, including feasibility studies, program evaluations, surveys, qualitative studies, and studies comparing the effectiveness of different routes of naloxone administration. We also included cost-effectiveness studies.
Results
We identified 41 articles that represented 5 categories: evaluations of OEND programs, effects of OEND programs on experiences and attitudes of participants, willingness of medical providers to prescribe naloxone, comparisons of different routes of naloxone administration, and the cost-effectiveness of naloxone.
Conclusions
Existing research suggests that people who are at risk for overdose and other bystanders are willing and able to be trained to prevent overdoses and administer naloxone. Counseling patients about the risks of opioid overdose and prescribing naloxone is an emerging clinical practice that may reduce fatalities from overdose while enhancing the safe prescribing of opioids.
OkieS. A flood of opioids, a rising tide of deaths. N Engl J Med.2010;363:1981–1985.
3.
PaulozziLJ, BudnitzDS, XiY. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf.2006;15:618–627.
4.
Centers for Disease Control and Prevention. Vital signs: risk for overdose from methadone used for pain relief—United States, 1999–2010. MMWR Morb Mortal Wkly Rep.2012;. 61:493–497.
5.
CalcaterraS, GlanzJ, BinswangerIA. National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999–2009. Drug Alcohol Depend.2013;131:263–270.
6.
WarnerM, ChenLH, MakucDM, AndersonRN, MiniñoAM. Drug Poisoning Deaths in the United States, 1980–2008. Hyattsville, MD: National Center for Health Statistics; 2011.
7.
JonesC, MackKA, PaulozziLJ. Pharmaceutical overdose deaths, United States, 2010. JAMA.2013;309:657–659.
8.
Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR Morb Mortal Wkly Rep.2011;60:1487–1492.
9.
CampanaM. Overdose mortality and naloxone distribution in Italy. Paper presented at Preventing Heroin Overdose: Pragmatic Approaches; January 13–14, 2000; . Seattle, WA.
10.
DarkeS, HallW. The distribution of naloxone to heroin users. Addiction.1997;92:1195–1199.
ThrockmortonDC, ComptonWM, LurieP. Management of opioid analgesic overdose. N Engl J Med.2012;367:1371; . author reply 1372–1373.
13.
Substance Abuse and Mental Health Services Administration. SAMHSA Opioid Overdose Prevention Toolkit. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014. HHS Publication No. (SMA) 13-4742.
14.
MathesonC, Pflanz-SinclairC, AucottL, . Reducing drug related deaths: a pre-implementation assessment of knowledge, barriers and enablers for naloxone distribution through general practice. BMC Fam Pract.2014;15:12.
15.
HansenA. Norway tries naloxone in spray form to prevent deaths from drug overdose. BMJ.2014;348:g1686.
16.
HåkanssonA, VedinA, WallinC, AhK. [Distribution of naloxone to prevent death from heroin overdose. Study of opioid dependent patients’ attitudes to be part of the antidote program]. Lakartidningen.2013;110:1340–1342.
DettmerK, SaundersB, StrangJ. Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. BMJ.2001;322:895–896.
19.
SealKH, DowningM, KralAH, . Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay area. J Urban Health.2003;80:291–301.
20.
TzemisD, Al-QutubD, AmlaniA, KesselringS, BuxtonJA. A quantitative and qualitative evaluation of the british columbia take home naloxone program. CMAJ Open.2014;2:E153–E161.
21.
LentonS, DietzeP, OlsenA, WigginsN, McDonaldD, FowlieC. Working together: expanding the availability of naloxone for peer administration to prevent opioid overdose deaths in the Australian capital territory and beyond. Drug Alcohol Rev.October 12014 . [Epub ahead of print].
22.
LiberatiA, AltmanDG, TetzlaffJ, . The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med.2009;151:W65–W94.
23.
GaleaS, WorthingtonN, PiperTM, NandiVV, CurtisM, RosenthalDM. Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in New York City. Addict Behav.2006;31:907–912.
24.
StrangJ, ManningV, MayetS, . Overdose training and take-home naloxone for opiate users: prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses. Addiction.2008;103:1648–1657.
25.
GastonRL, BestD, ManningV, DayE. Can we prevent drug related deaths by training opioid users to recognise and manage overdoses?Harm Reduct J.2009;6:26.
26.
BennettAS, BellA, TomediL, HulseyEG, KralAH. Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania. J Urban Health.2011;88:1020–1030.
27.
BennettT, HollowayK. The impact of take-home naloxone distribution and training on opiate overdose knowledge and response: an evaluation of the thn project in Wales. Drugs Educ Prev Policy.2012;19:320–328.
28.
Doe-SimkinsM, WalleyAY, EpsteinA, MoyerP. Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health.2009;99:788–791.
29.
EnteenL, BauerJ, McLeanR, . Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health.2010;87:931–941.
30.
HellerDI, StancliffS. Providing naloxone to substance users for secondary administration to reduce overdose mortality in New York City. Public Health Rep.2007;122:393–397.
31.
LankenauSE, WagnerKD, SilvaK, . Injection drug users trained by overdose prevention programs: responses to witnessed overdoses. J Community Health.2013;38:133–141.
32.
LeecePN, HopkinsS, MarshallC, OrkinA, GassanovMA, ShahinRM. Development and implementation of an opioid overdose prevention and response program in Toronto, Ontario. Can J Public Health.2013;104:e200–e204.
33.
MaxwellS, BiggD, StanczykiewiczK, Carlberg-RacichS. Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. J Addict Dis.2006;25:89–96.
34.
PiperTM, RudenstineS, StancliffS, . Overdose prevention for injection drug users: lessons learned from naloxone training and distribution programs in New York City. Harm Reduct J.2007;4:3.
35.
SealKH, ThawleyR, GeeL, . Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health.2005;82:303–311.
36.
YokellMA, GreenTC, BowmanS, McKenzieM, RichJD. Opioid overdose prevention and naloxone distribution in Rhode Island. Med Health R I.2011;94:240–242.
37.
WalleyAY, Doe-SimkinsM, QuinnE, PierceC, XuanZ, OzonoffA. Opioid overdose prevention with intranasal naloxone among people who take methadone. J Subst Abuse Treat.2013;44:241–247.
38.
AlbertS, BrasonFW2nd, SanfordCK, DasguptaN, GrahamJ, LovetteB. Project Lazarus: community-based overdose prevention in rural North Carolina. Pain Med.2011;12(Suppl 2):S77–S85.
39.
McAuleyA, LindsayG, WoodsM, LouttitD. Responsible management and use of a personal take-home naloxone supply: a pilot project. Drugs.2010;17:388–399.
40.
WalleyAY, XuanZ, HackmanHH, . Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in massachusetts: interrupted time series analysis. BMJ.2013;346:f174.
41.
KerrD, DietzeP, KellyAM, JolleyD. Attitudes of Australian heroin users to peer distribution of naloxone for heroin overdose: perspectives on intranasal administration. J Urban Health.2008;85:352–360.
42.
WakemanSE, BowmanSE, McKenzieM, JeronimoA, RichJD. Preventing death among the recently incarcerated: an argument for naloxone prescription before release. J Addict Dis.2009;28:124–129.
43.
LaguT, AndersonBJ, SteinM. Overdoses among friends: drug users are willing to administer naloxone to others. J Subst Abuse Treat.2006;30:129–133.
44.
StrangJ, PowisB, BestD, . Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. Addiction.1999;94:199–204.
45.
BacaCT, GrantKJ. What heroin users tell us about overdose. J Addict Dis.2007;26:63–68.
46.
PiperTM, StancliffS, RudenstineS, . Evaluation of a naloxone distribution and administration program in New York City. Subst Use Misuse.2008;43:858–870.
47.
TobinKE, GaaschWR, ClarkeC, MacKenzieE, LatkinCA. Attitudes of emergency medical service providers towards naloxone distribution programs. J Urban Health.2005;82:296–302.
48.
WagnerKD, ValenteTW, CasanovaM, . Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA. Int J Drug Policy.2010;21:186–193.
49.
GreenTC, HeimerR, GrauLE. Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States. Addiction.2008;103:979–989.
50.
KimD, IrwinKS, KhoshnoodK. Expanded access to naloxone: options for critical response to the epidemic of opioid overdose mortality. Am J Public Health.2009;99:402–407.
51.
ShermanSG, GannDS, TobinKE, LatkinCA, WelshC, BielensonP. “The life they save may be mine”: diffusion of overdose prevention information from a city sponsored programme. Int J Drug Policy.2009;20:137–142.
52.
ShermanSG, GannDS, ScottG, CarlbergS, BiggD, HeimerR. A qualitative study of overdose responses among Chicago IDUs. Harm Reduct J.2008;5:2.
53.
TobinKE, ShermanSG, BeilensonP, WelshC, LatkinCA. Evaluation of the staying alive programme: training injection drug users to properly administer naloxone and save lives. Int J Drug Policy.2009;20:131–136.
54.
BeletskyL, RuthazerR, MacalinoGE, RichJD, TanL, BurrisS. Physicians’ knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: challenges and opportunities. J Urban Health.2007;84:126–136.
55.
CoffinPO, FullerC, VadnaiL, BlaneyS, GaleaS, VlahovD. Preliminary evidence of health care provider support for naloxone prescription as overdose fatality prevention strategy in New York City. J Urban Health.2003;80:288–290.
56.
GreenTC, BowmanSE, ZallerND, RayM, CaseP, HeimerR. Barriers to medical provider support for prescription naloxone as overdose antidote for lay responders. Subst Use Misuse.2013;48:558–567.
57.
LoimerN, HofmannP, ChaudhryHR. Nasal administration of naloxone is as effective as the intravenous route in opiate addicts. Int J Addict.1994;29:819–827.
58.
LeavittSB. Intranasal naloxone for at-home opioid rescue. Pract Pain Manag.2010;46.
59.
KellyAM, KerrD, DietzeP, PatrickI, WalkerT, KoutsogiannisZ. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med J Aust.2005;182:24–27.
60.
KerrD, DietzeP, KellyAM. Intranasal naloxone for the treatment of suspected heroin overdose. Addiction.2008;103:379–386.
61.
WermelingDP. Opioid harm reduction strategies: focus on expanded access to intranasal naloxone. Pharmacotherapy.2010;30:627–631.
62.
BartonED, ColwellCB, WolfeT, . Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. J Emerg Med.2005;29:265–271.
63.
BuajordetI, NaessAC, JacobsenD, BrorsO. Adverse events after naloxone treatment of episodes of suspected acute opioid overdose. Eur J Emerg Med.2004;11:19–23.
64.
KerrD, KellyAM, DietzeP, JolleyD, BargerB. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction.2009;104:2067–2074.
65.
MerlinMA, SayboltM, KapitanyanR, . Intranasal naloxone delivery is an alternative to intravenous naloxone for opioid overdoses. Am J Emerg Med. Mar 2010;28:296–303.
66.
CoffinPO, SullivanSD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med.2013;158:1–9.
67.
CoffinPO, SullivanSD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal in Russian cities. J Med Econ.2013;16:1051–1060.
68.
Advisory Council on the Misuse of Drugs. Consideration of Naloxone. London: Advisory Council on the Misuse of Drugs; 2012.
69.
BurrisS, BeletskyL, CastagnaC, CoyleC, CroweC, McLaughlinJ. Stopping an invisible epidemic: legal issues in the provision of naloxone to prevent opioid overdose. Drexel Law Rev.2009;1:273–339.
DavisC, WebbD, BurrisS. Changing law from barrier to facilitator of opioid overdose prevention. J Law Med Ethics.2013;41(Suppl 1):33–36.
72.
BazaziAR, ZallerND, FuJJ, RichJD. Preventing opiate overdose deaths: examining objections to take-home naloxone. J Health Care Poor Underserved.2010;21:1108–1113.
73.
DasguptaN, SanfordC, AlbertS, BrasonFWII. Opioid drug overdoses: a prescription for harm and potential for prevention. Am J Lifestyle Med.2010;4:32–37.
74.
WrightN, OldhamN, FrancisK, JonesL. Homeless drug users’ awareness and risk perception of peer “take home naloxone” use—a qualitative study. Subst Abuse Treat Prev Policy.2006;1:28.
GreenTC, ZallerN, RichJ, BowmanS, FriedmannP. Revisiting Paulozzi et al.'s “Prescription drug monitoring programs and death rates from drug overdose”. Pain Med.2011;12:982–985.
CiceroTJ, EllisMS, SurrattHL. Effect of abuse-deterrent formulation of oxycontin. N Engl J Med.2012;367:187–189.
79.
KnopfA. Naloxone auto-injector gains fda approval. Behav Healthc.2014;34:48–49.
80.
BeletskyL, RichJD, WalleyAY. Prevention of fatal opioid overdose. JAMA.2012;308:1863–1864.
81.
GeorgeS, MoreiraK. A guide for clinicians on “take home” naloxone prescribing. Addict Disord Their Treat.2008;7:163–167.
82.
WorthingtonN, Markham PiperT, GaleaS, RosenthalD. Opiate users’ knowledge about overdose prevention and naloxone in New York City: a focus group study. Harm Reduct J.2006;3:19.
83.
Substance Abuse and Mental Health Services Administration Office of Applied Studies. Drug Abuse Warning Network, 2003: Area Profiles of Drug-Related Mortality. Rockville, MD: United States Department of Health and Human Services; 2005.
84.
CoffinPO, TracyM, BucciarelliA, OmpadD, VlahovD, GaleaS. Identifying injection drug users at risk of nonfatal overdose. Acad Emerg Med.2007;14:616–623.
85.
DarkeS, HallW. Heroin overdose: research and evidence-based intervention. J Urban Health.2003;80:189–200.
86.
SporerKA. Acute heroin overdose. Ann Intern Med.1999;130:584–590.
87.
DarkeS, MillsKL, RossJ, TeessonM. Rates and correlates of mortality amongst heroin users: findings from the Australian Treatment Outcome Study (ATOS), 2001–2009. Drug Alcohol Depend.2011;115:190–195.
88.
BohnertAS, TracyM, GaleaS. Characteristics of drug users who witness many overdoses: implications for overdose prevention. Drug Alcohol Depend.2012;120:168–173.
89.
StrangJ, McCambridgeJ, BestD, . Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ.2003;326:959–960.
90.
BinswangerIA, SternMF, DeyoRA, . Release from prison—a high risk of death for former inmates. N Engl J Med.2007;356:157–165.
91.
BinswangerIA, NowelsC, CorsiKF, . Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addict Sci Clin Pract.2012;7:3.
92.
BohnertAS, ValensteinM, BairMJ, . Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA.2011;305:1315–1321.
93.
DunnKM, SaundersKW, RutterCM, . Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med.2010;152:85–92.
94.
EvansJL, TsuiJI, HahnJA, DavidsonPJ, LumPJ, PageK. Mortality among young injection drug users in San Francisco: a 10-year follow-up of the UFO study. Am J Epidemiol.2012;175:302–308.
95.
HallAJ, LoganJE, ToblinRL, . Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA.2008;300:2613–2620.
96.
GreenTC, GrauLE, CarverHW, KinzlyM, HeimerR. Epidemiologic trends and geographic patterns of fatal opioid intoxications in Connecticut, USA: 1997–2007. Drug Alcohol Depend.2011;115:221–228.
97.
Warner-SmithM, DarkeS, LynskeyM, HallW. Heroin overdose: causes and consequences. Addiction.2001;96:1113–1125.
98.
ToblinRL, PaulozziLJ, LoganJE, HallAJ, KaplanJA. Mental illness and psychotropic drug use among prescription drug overdose deaths: a medical examiner chart review. J Clin Psychiatry.2010;71:491–496.
HavensJR, OserCB, KnudsenHK, . Individual and network factors associated with non-fatal overdose among rural Appalachian drug users. Drug Alcohol Depend.2011;115:107–112.
101.
ChanGM, StajicM, MarkerEK, HoffmanRS, NelsonLS. Testing positive for methadone and either a tricyclic antidepressant or a benzodiazepine is associated with an accidental overdose death: analysis of medical examiner data. Acad Emerg Med.2006;13:543–547.
